Skip to content
An Initiative of AVAC
Search
Back to Country Data

Country Overview:
Uganda

Global PrEP Tracker
Last Updated: 19 June 2025

Drug Registration Status

Approved
Pending
Not
Approved
Lenacapavir (LEN) for PrEP — Gilead
Data Not Available
Cabotegravir (CAB) for PrEP — ViiV
Approved 2024 2024
Dapivirine Vaginal Ring (DVR) — Pop Council
Approved 2021 2021
Oral PrEP TDF/FTC — Gilead (Truvada)
Approved 2017 2017
Oral PrEP TDF/xTC* - generic
Approved
Oral PrEP F/TAF — Gilead
Not Approved
* TDF/xTC refers to tenofovir disoproxil fumarate (TDF) and either emtricitabine (FTC) or lamivudine (3TC)

Research, Demonstration and Implementation

Oral PrEP

6 Completed Projects

Dapivirine Vaginal Ring

2 Planned/Ongoing Projects

Injectable PrEP

4 Planned/Ongoing Projects

Policy Frameworks

Consolidated Guidelines for Prevention and Treatment of HIV in Uganda, 2020

National HIV/AIDS Strategic Plan 2015/16 – 2019/20

Technical Guidance on PrEP for Persons at Substantial Risk of HIV in Uganda, 2022

Est. Cumulative
Initiations:

Total PrEP: 743,696

Oral PrEP: 743,636

Dapivirine Vaginal Ring: 60

Injectable PrEP: N/A

Featured Resources

Document

Uganda Strategic Direction Summary, 2023

Uganda continues to accelerate reductions in new HIV infections and AIDS-related deaths, despite chronic infectious disease outbreaks, health system stressors, and economic fragility. This is reflected in Uganda’s HIV clinical cascade, which demonstrates substantial progress in finding, diagnosing, and successfully treating people living with HIV (PLHIV) since 2016. Today, an estimated 92% of Ugandans living…
Document

Uganda Monitoring & Evaluation Plan 2020-25

Having come close to achieving 95:95:95 by 2020, Uganda launched an set of two plans to achieve 95:95:95 in the coming decade, with a special focus on children. The first plan is the National HIV and AIDS Strategic Plan and the second is this Monitoring and Evaluation Plan (M&E Plan). This M&E Plan seeks to…
Document

Dapivirine Ring Early Introduction Considerations — Uganda Analysis

The OPTIONS Consortium conducted secondary research and interviews with key stakeholders in several countries to understand questions about the ring that could inform demonstration and processes for introducing new biomedical HIV prevention products. Uganda was prioritized for analysis due to the state of the HIV epidemic in the country and experience with ring trials. (For…
Document

Digital Health Landscaping Report

This landscape analysis aimed to identify common virtual channels used in several countries, estimate the number of users of each channel, and categorize countries into one of three groups based on potential for interventions to use virtual channels to succeed. Users were defined as adolescent girls and young women (aged 15–24), pregnant or breastfeeding people…
Document

New PrEP Product Implementation Roadmap for PrEP vaginal ring and CAB for PrEP in Uganda

This presentation outlines the timelines for implementation of the dapivirine vaginal ring and cabotegravir (CAB) for PrEP in Uganda.
View All Resources